Search clinical trials for: Glycogen Storage Disease Type I
Total 497070 results
-
Ultragenyx Pharmaceutical IncActive, not recruitingGlycogen Storage Disease Type IA | Von Gierke's Disease (GSD Type Ia)Netherlands, United States, Canada, Spain
-
Sanguine BiosciencesTerminatedGlycogen Storage Disease Type IBUnited States
-
Ultragenyx Pharmaceutical IncTerminatedGlycogen Storage Disease Type IIIUnited States, Spain, Italy
-
Amicus TherapeuticsActive, not recruitingPompe DiseaseUnited States, Netherlands, United Kingdom, Australia, Germany, New Zealand
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II;Pompe's DiseaseCzechia, Taiwan, Belgium, Germany, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, Denmark, France, Hungary, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Russian Federation, Spain, Switzerland, Turk... and more
-
RTI InternationalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsEnrolling by invitationPrimary Hyperoxaluria Type 3 | Diabetes Mellitus | Hemophilia A | Hemophilia B | Hereditary Fructose Intolerance | Cystic Fibrosis | Factor VII Deficiency | Phenylketonurias | Sickle Cell Disease | Dravet Syndrome | Duchenne Muscular Dystrophy | Prader-Willi Syndrome | Fragile X Syndrome | Chronic Granulomatous Disease and other conditionsUnited States
-
Amicus TherapeuticsActive, not recruitingPompe Disease (Late-onset)United States, Germany, Taiwan, Belgium, Australia, Slovenia, Spain, Netherlands, Hungary, Japan, Austria, United Kingdom, France, Argentina, Canada, Sweden, Denmark, New Zealand, Greece, Korea, Republic of, Bosnia and Herzegovina, Ita... and more
-
Genzyme, a Sanofi CompanyCompleted
-
Genzyme, a Sanofi CompanyActive, not recruiting
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II Pompe DiseaseUnited States, Belgium, Denmark, France, Germany, Netherlands, United Kingdom
-
Rigshospitalet, DenmarkCompletedGlycogen Storage Disease Type IIIDenmark
-
Rigshospitalet, DenmarkUltragenyx Pharmaceutical IncCompletedTarui Disease | Debrancher Deficiency | GYG1 DEFICIENCYDenmark
-
SanofiCompletedPompe Disease | Mucopolysaccharidosis Type I (MPS I)Italy
-
University Children's Hospital, ZurichSanofiCompleted
-
Rocket Pharmaceuticals Inc.Completed
-
Spark TherapeuticsActive, not recruitingLysosomal Storage Diseases | Glycogen Storage Disease Type II | Glycogen Storage Disease Type 2 | Pompe Disease (Late-onset) | Pompe Disease | LOPD | Acid Maltase DeficiencyUnited States, Canada, Netherlands, France, Denmark, Germany, Italy, United Kingdom
-
Duke UniversityGenzyme, a Sanofi CompanyActive, not recruitingPompe Disease (Late-onset) | Pompe Disease | GAA DeficiencyUnited States
-
Ultragenyx Pharmaceutical IncTerminatedGlycogen Storage Disease Type IIIUnited States, Netherlands
-
Genzyme, a Sanofi CompanyActive, not recruitingGlycogen Storage Disease Type IIFrance
-
Hospital de Clinicas de Porto AlegreConselho Nacional de Desenvolvimento Científico e Tecnológico; Fundação Médica...CompletedGlycogen Storage Disease Type IBrazil
-
Amicus TherapeuticsCompletedPompe Disease (Late-onset)United States, Australia, Korea, Republic of, Japan, Taiwan, Belgium, Slovenia, New Zealand, United Kingdom, France, Argentina, Canada, Spain, Bosnia and Herzegovina, Germany, Sweden, Hungary, Austria, Bulgaria, Denmark, Greece, I... and more
-
University of FloridaEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Amicus TherapeuticsAvailablePompe Disease Infantile-OnsetTaiwan, United States, Italy
-
Amicus TherapeuticsAvailable
-
Genzyme, a Sanofi CompanyActive, not recruitingGlycogen Storage Disease Type II-Pompe's DiseaseUnited States, France, Japan, Taiwan, United Kingdom
-
Asklepios Biopharmaceutical, Inc.Active, not recruiting
-
Ultragenyx Pharmaceutical IncTerminatedWilson Disease | Ornithine Transcarbamylase Deficiency | Glycogen Storage Disease Type IASpain, United Kingdom, Canada, United States, Brazil
-
Duke UniversityCompleted
-
Spark TherapeuticsCompletedLysosomal Storage Diseases | Glycogen Storage Disease Type 2 | Pompe Disease (Late-onset) | Pompe Disease | LOPD | Acid Maltase DeficiencyUnited States, Italy, United Kingdom, Netherlands, France, Germany
-
Genzyme, a Sanofi CompanyCompletedPompe Disease | Glycogen Storage Disease Type II (GSD II) | Acid Maltase DeficiencyUnited States, Belgium, Denmark, France, Germany, Netherlands, United Kingdom
-
Centre Hospitalier Universitaire de NiceCompleted
-
Rocket Pharmaceuticals Inc.Active, not recruitingDanon DiseaseUnited States
-
CENTOGENE GmbH RostockWithdrawnFructose Metabolism, Inborn Errors | Glycogen Storage Disease Type II | Glycogen Storage Disease | Glycogen Storage Disease Type V | Glycogen Storage Disease Type I | Glycogen Storage Disease Type III | Glycogen Storage Disease Type VII | Glycogen Storage Disease Type IV | Glycogen Storage Disease Type... and other conditionsGermany, India, Sri Lanka
-
Rigshospitalet, DenmarkUniversity College, LondonCompletedMcArdle DiseaseDenmark, United Kingdom
-
Nicoline LøkkenCompleted
-
Rigshospitalet, DenmarkCompleted
-
CENTOGENE GmbH RostockWithdrawnLung Disease | Cerebral Aneurysm | Macroglossia | Cardiac Diseases | Obstructive Sleep Apnoea | Muscular Weakness | Hepato-splenomegalyGermany, India, Sri Lanka
-
BioMarin PharmaceuticalTerminatedLate-onset Pompe DiseaseUnited States, United Kingdom
-
Ultragenyx Pharmaceutical IncCompletedGSD1Netherlands, United States, Canada, Spain
-
Mads Peter Godtfeldt StemmerikEdgewise Therapeutics, Inc.CompletedBecker Muscular Dystrophy | McArdle Disease | Limb-Girdle Muscular Dystrophy Type 2Denmark
-
Turkish Society of Pediatric Gastroenterology,...CompletedDuchenne Muscular Dystrophy | Pompe Disease (Late-onset)Turkey
-
Ultragenyx Pharmaceutical IncCompletedGlycogen Storage Disease Type IIIUnited States
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Pompe DiseaseUnited States
-
LMU KlinikumCompletedHealthy | Myotonic Dystrophy Type 2 | Pompe Disease (Late-onset) | Spinal Muscular Atrophy Type 3 | Myotonic Dystrophy Type 1 (DM1) | Facioscapulohumeral Muscular Dystrophy 1 | Inclusion Body Myositis, SporadicGermany
-
Duke UniversityWithdrawnPompe Disease (Late-onset)United States
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIChina
-
Genzyme, a Sanofi CompanyTerminatedGlycogen Storage Disease Type II (GSD-II) | Pompe Disease | Glycogenesis 2 Acid Maltase DeficiencyUnited States, Israel
-
University of FloridaLacerta TherapeuticsCompletedPompe DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompletedPompe Disease | Glycogen Storage Disease Type II (GSD II)United States, Russian Federation, United Kingdom, Bulgaria, India, Ukraine
-
University Medical Center GroningenUltragenyx Pharmaceutical IncCompletedGlycogen Storage Disease Type IANetherlands